When Supply Chain Becomes a Clinical Choice: Governance, Predictability, and the Patient Divide
From Out of the Lab Podcast · 00:45:43
Show by Out of the Lab Media Group
In this episode of Out of the Lab, host Nicholas Crudele sits down with repeat guests Carl, Hedley, and Angeliki to unpack the friction points across the cell and gene therapy supply chain. Moving beyond standard logistics, the panel explores why every supply chain decision is ultimately a clinical one, how operational unpredictability fuels physician referral hesitation, and why the disconnect between healthcare delivery and biomanufacturing systems must be bridged.Key Takeaways:Why a failed manufacturing run in autologous cell therapy represents a lost patient option rather than a simple shortage.The structural divide between hospital systems and biomanufacturing license holders.How supply chain unpredictability translates directly into clinical risk for physicians.The necessity of medical governance and the impact of patient starting material variability.Timestamps & Topics:00:00:00 – Introduction & Method Made Operational Intelligence00:01:36 – Logistical Friction Points & Human Handoffs in Autologous Therapies00:03:05 – The Structural Divide Between Healthcare Systems and Production00:04:26 – Every Supply Chain Decision as a Clinical Choice00:06:23 – Medical Governance and Decision-Making Authority00:11:37 – Integrating GMP & GDP Skills into Healthcare Settings00:18:37 – Starting Material as the Ultimate Manufacturing Wild Card00:21:25 – Physician Hesitation: Unpredictability vs. Efficacy00:23:08 – Cold Chain Realities and Wholesale Infrastructure Limits00:30:31 – Incremental Optimization vs. Rebuilding the Supply Chain
More episodes of Out of the Lab Podcast
More episodes
- Solving the CGT Workforce Deficit & 50% CAR-T Attrition Gap | Dr. Shernan Holtan
- In Vivo Lenti, COGS Reduction, and the End Game Mindset with Ethan (Minaris)
- Rare Disease Commercialization: Lean Market Entry & Virtual Subsidiaries | Chad (ChangDeok) Ji
- Point-of-Care Bottlenecks, Portal Fatigue & SOP Ambiguity with Dr. Patrick Hanley
- Restoring Patient Agency: Breaking the 80% Access Barrier in Cell Therapy | Michelle Hill
- The 2 AM Audit Reality: Ex-FDA Regulators on CDMO Oversight, Night Shift Sins, and Data Integrity
- The $1M CDMO Selection Trap & Rethinking CMC Roadmaps with Shri Joshi
- Bunny Suits, Ice Buckets, and Slashing COGS: Bridging R&D and GMP Realities with Jerry (CellBri)
- What Cell & Gene Therapy Can Learn About Tech Transfer From Biofuels
- Tech Transfer in Cell & Gene Therapy
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.